CONTROL BIONICS LIMITED — Capital/Financing Update 2024

Aug 13, 2024

==> picture [145 x 45] intentionally omitted <==

14 August 2024

ASX ANNOUNCEMENT

ISSUE OF OPTIONS EMPLOYEE SHARE OPTION PLAN

The Board of Control Bionics Ltd ( CBL ) has issued the following options to 5 employees pursuant to the CBL Employee Share Option Plan.

Number: 1,226,414

Exercise price: Each option converts to one fully paid CBL ordinary share on payment of 5.3c per share

Vesting date: 25% of options issued will vest at each of the first four anniversaries from the date of issue Expiry date: Five years from date of issue

The Board has, subject to shareholder approval, agreed to issue 1,698,113 options to the CBL CEO, Jeremy Steele, pursuant to the CBL Employee Share Option Plan on identical terms to the above options. It is expected that approval of shareholders will be sought at the 2024 AGM.

This announcement was authorised by CBL Chairman, Roger Hawke.

About Control Bionics:

Control Bionics is a medical device company dedicated to assisting patients whose ability to communicate is compromised by conditions such as Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS). Our core patented NeuroNode technology is a wireless, wearable device that detects minute signals sent from the brain to any skeletal muscle, capturing EMG (Electromyography) output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Our technology integrates eye gaze technology, allowing the eye gaze to move a cursor on a computer screen, while the NeuroNode acts as a mouse button. Control Bionics uniquely combines touch, eye, and NeuroNode control, offering patients the ability to express themselves with significantly faster speed and less fatigue.

We have recently expanded our offering to include mobility solutions with the launch of DROVE (now TGA approved), an autonomous wheelchair module that allows powered wheelchair users to operate their wheelchairs independently in their own homes.

Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip ® . This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.

Control Bionics operates in North America, Australia, Singapore, and Japan.

Control Bionics Limited Registered Office: Level 4, 11-13 Pearson St, Cremorne, Victoria, 3121, Australia T: +61 3 9897 3576 W: www.controlbionics.com ABN: 45 115 465 462

Investors and Media

Jeremy Steele – CEO and Managing Director jsteele@controlbionics.com

Brett Crowley – Company Secretary brettcrowley@controlbionics.com

Investor Relations:

Joe Durak Executive Director & Founder Lynx Advisors joe@lynxadvisors.com.au +61 414 465 582

For further information, visit our website: www.controlbionics.com

Control Bionics Limited Registered Office: Level 4, 11-13 Pearson St, Cremorne, Victoria 3121, Australia T: +61 3 9897 3576 W: www.controlbionics.com ABN: 45 115 465 462

For further information visit the website: https://www.controlbionics.com/